Neovasc Inc (NASDAQ: NVCN) is having a great day in the market today, and for good reason. The company announced the publication of a report in a peer reviewed journal, exciting investors who are sending the stock for the top. Today, we’ll talk about:
- The publication;
- what we’re seeing from NVCN stock as a result; and
- what we’ll be watching for haead.
NVCN Announces Journal Publication
As mentioned above, Neovasc is having a great start to the trading session this morning after announcing the publication of a paper in a peer reviewed journal. The publication was announced by way of press release early this morning.
In the release, NVCN said that the European Heart Journal, Quality of Care and Clinical Outcomes, has published a peer-reviewed article surrounding its Reducer. The article suggests that the Reducer is an effective therapy for patients suffering from refractory angina. Moreover, the paper suggests that the Reducer has a positive impact on healthcare burden.
The article is titled “Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients.” The authors of the article found that the Reducer decreases healthcare burden of patients and the associated costs across a range of European healthcare system perspectives. The article also outlined that the Reducer is cost-effective according to the cost-effective thresholds of the World Health Organization.
The study indicated that the Reducer reduces healthcare resource utilization and associated costs in patients with severe angina, refractory to optimal medical therapy and not amenable for further revascularization.
In a statement, Fred Colen, President and CEO at NVCN, had the following to offer:
This study indicates that the Reducer not only significantly improves quality of life for patients suffering from refractory angina, but that treatment with the Reducer also results in improved quality-adjusted-life-year values, and in statistically significant savings in healthcare costs related to angina-driven hospitalizations, outpatient visits, coronary angiograms and percutaneous coronary interventions, per patient-year.
Furthermore, as of the second year, the incremental cost-effectiveness ratio for patients with the Reducer is well below the levels established by the WHO and well below the even stricter Dutch threshold.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news leads to moves. When it comes to Neovasc, the news proved to be positive.
After all, the article suggesting a reduced cost burden for patients with severe angina is a great selling point for the company’s Reducer product. So, it’s not surprising to see that excited investors are pushing the stock on a run for the top.
As is just about always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (9:45), NVCN is trading at $0.54 per share after a gain of $0.027 per share or 5.33% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on NVCN. In particular, we’re interested in following the story surrounding the company’s continued work to bring value to investors through the Reducer and the rest of its product pipeline. Nonetheless, we’ll keep a close eye on the story and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!